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Weight gain and metabolic complications are major adverse effects of many psychotropic drugs. We aimed to understand how
socio-economic status (SES), defined as the Swiss socio-economic position (SSEP), is associated with cardiometabolic parameters
after initiation of psychotropic medications known to induce weight gain. Cardiometabolic parameters were collected in two
Swiss cohorts following the prescription of psychotropic medications. The SSEP integrated neighborhood-based income,
education, occupation, and housing condition. The results were then validated in an independent replication sample
(UKBiobank), using educational attainment (EA) as a proxy for SES. Adult patients with a low SSEP had a higher risk of developing
metabolic syndrome over one year versus patients with a high SSEP (Hazard ratio (95% CI)= 3.1 (1.5–6.5), n= 366). During the
first 6 months of follow-up, a significant negative association between SSEP and body mass index (BMI), weight change, and
waist circumference change was observed (25 ≤ age < 65, n= 526), which was particularly important in adults receiving
medications with the highest risk of weight gain, with a BMI difference of 0.86 kg/m2 between patients with low versus high
SSEP (95% CI: 0.03–1.70, n= 99). Eventually, a causal effect of EA on BMI was revealed using Mendelian randomization in the
UKBiobank, which was notably strong in high-risk medication users (beta: −0.47 SD EA per 1 SD BMI; 95% CI: −0.46 to −0.27,
n= 11,314). An additional aspect of personalized medicine was highlighted, suggesting the patients’ SES represents a significant
risk factor. Particular attention should be paid to patients with low SES when initiating high cardiometabolic risk psychotropic
medications.
Translational Psychiatry ; https://doi.org/10.1038/s41398-021-01482-9
INTRODUCTION
In psychiatric populations (comprising schizophrenia, bipolar disorder,
major depressive disorder, and their related spectrum disorders) life
expectancy is reduced by about ≥10 years versus the general
population. Approximately two-thirds of this mortality is attributed to
cardiovascular diseases [1]. This increase in cardiometabolic-related
health problems is multidetermined, including psychiatric illness,
lifestyle, and diet behaviors, resulting in a high prevalence of obesity
and other cardiometabolic risk factors [2]. In addition, many
psychotropic medications (most antipsychotics, some mood stabi-
lizers, and antidepressants) can worsen weight, body mass index
(BMI), waist circumference (WC), lipid, and glucose profiles [2].
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Social factors, such as low educational attainment (EA) or low
income, have been associated with poor mental health outcomes
and depression [3]. Some studies also linked socio-economic
status (SES) with the risk of or severity of symptoms in
schizophrenia and other mental disorders [4, 5]. Moreover, SES is
a moderator of obesity in the general population [6]. In the area of
Lausanne, Switzerland, geographic clusters of high versus low
BMIs were observed, which were influenced by neighborhood-
level income [7]. Similar results were reported in another Swiss
study, performed on young men using conscription data [8],
showing substantial spatial variations in obesity risk, which
increased with lower SES. These studies suggest an influence of
SES on both mental health and obesity. Nevertheless, associations
between SES and cardiometabolic parameters in patients treated
with psychotropic medications are under-researched.
One study found that social determinants of health were
inversely associated with glycated hemoglobin in first-episode
psychosis [9]. However, patients had very short prior psychotropic
treatment exposure and the cross-sectional design precluded the
investigation of the impact of SES factors on treatment-related
metabolic health evolution. Another study conducted in treated
bipolar patients revealed an inverse correlation between normal
weight, overweight, obesity, or extreme obesity and income level
[10]. However, this finding did not remain significant when
adjusting for site of inclusion and eating disorder diagnoses.
Besides, no other SES factors, such as EA, occupation, or housing
condition, were characterized in this study. In a third study, using
multivariable modeling, housing condition was significantly
associated with weight gain during 6-month olanzapine therapy
in patients with schizophrenia and bipolar disorders [11].
To better address the impact of SES, we aimed to longitudinally
explore whether and how SES is associated with cardiometabolic
variables in a psychiatric cohort treated with psychotropic
medications, which can induce weight gain, and explore mediat-
ing effects of high-, medium- and low-risk medications. Finally, we
sought to validate our epidemiological associations in the
UKBiobank (UKB), a very large population-based cohort. Based
on the prior literature, we hypothesized that weight gain following
psychotropic medication initiation would be inversely related to
SES and that this effect would be most pronounced with high
cardiometabolic risk medications.
METHODS
Psychiatric population and metabolic outcomes
A departmental guideline, adopted in 2007 in the Department of
Psychiatry at Lausanne University Hospital, requires the monitoring of
metabolic adverse effects when patients start a psychotropic treatment
known to induce weight gain and/or worsen other metabolic parameters.
In- and outpatients starting such treatments are thus followed with routine
check-ups at baseline and after 1, 2, 3, 6, and 12 months. Body weight, BMI,
WC, blood pressure, and plasma levels of glucose and lipids (low-density
lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL),
total cholesterol, and triglycerides) are monitored routinely at these same
time points.
Informed consent was obtained from prospectively followed patients
between 4/2007 and 10/2016 (PsyMetab, n= 1093) as previously
described [12]. Because of the non-interventional post-hoc analysis
design, the requirement of informed consent was waived for patients
routinely assessed as part of clinical care between 4/2007 and 12/2015
(PsyClin, n= 714). Data use in both cohorts was approved by the Ethics
Committee of the Canton of Vaud. Patients selection is described in
Supplementary Fig. 1.
Medication, diagnosis, age at medication onset, smoking status, and
sex were extracted from medical files and/or specific questionnaires.
Diagnostic groups were established according to ICD-10 classification,
and psychotropic medications were classified, independently of daily
dosage, according to their risk for inducing weight gain in three
categories, i.e., low-risk (e.g., amisulpride, aripiprazole, haloperidol,
lurasidone, and flupentixol); medium-risk (e.g., quetiapine, risperidone,
paliperidone, lithium, mirtazapine, zuclopenthixol, and levomeproma-
zine), and high-risk (e.g., valproate, olanzapine, and clozapine) as
previously described [13].
SES: assignment of the SSEP index
Research conducted in Switzerland aimed to determine individual’s SES
based on postal address [14]. An area-based index of Swiss socio-economic
position (SSEP) was developed, ranging between 0 (most disadvantaged)
and 100 (most privileged). The characterization of the SSEP index by place
of residency was based on 2000 census data including income, education,
occupation, and housing conditions. The validity of the SSEP index was
then demonstrated to be associated with all-cause and cause-specific
mortality [14].
To estimate patients’ SES, postal addresses were obtained and geocoded
using Google API via the ggmap R package [15]. Patients with no available
personal address were excluded (Supplementary Fig. 1). Each geocoded
postal address was matched with a SSEP according to the minimum
distance to a reference SSEP building, with a maximum distance of 130.5
meters, as previously described [14].
Statistical analyses
Baseline demographic variables of patients were compared with their SSEP
level (below or above the median SSEP) using the χ2 test of independence
for categorical variables and Student’s t-tests for continuous variables.
Incidence of metabolic syndrome, according to the International
Diabetes Federation (IDF) definition [16], as well as the incidence of each
individual component of metabolic syndrome was investigated in adult
patients (25–65-years old) with low versus high SSEP during the first year
of treatment. The Cox proportional hazard model was used, adjusted for
confounding variables (age, sex, first available BMI, diagnosis, and
treatment categories).
Linear mixed effect models were then used to assess the effect of SSEP
on each cardiometabolic parameter during 1–6 months of medications
treatment, adjusting for confounding variables (age, sex, baseline BMI,
diagnosis, and treatment categories; see Supplementary Appendix). We
used the SSEP variable once on a continuous and once on a categorical
scale: (a) low SSEP (i.e., SSEP below the first quartile), (b) medium SSEP (i.e.,
SSEP in the second or third quartile), and (c) high SSEP (i.e., SSEP above the
third quartile). Analyses were performed independently in three age
groups, young patients (<25 years old), adults 25 to <65 years old, and
senior patients ≥65 years old, as the meaning of the SSEP construct varies
for different birth cohorts [14]. In adults, subgroup analyses were also run
to differentiate the effect on BMI, weight, and WC according to initial BMI
and according to treatment categories. All analyses were two-sided with
alpha= 0.05. Analyses were performed using the R environment for
statistical computing version 3.5.2.
Validation in the UKB sample
We sought to validate our associations in the UKB sample and also aimed
to estimate a causal effect through Mendelian randomization (MR). The
details of the UKB have been described elsewhere [17]. Briefly, UKB is a
prospective cohort study including more than 500,000 individuals (40–69
years) recruited from the United Kingdom during 2006–2010. We selected
participants according to quality measures, ethnicity, and relatedness. We
then defined a psychiatric population within the UKB based on reported
psychotropic medication use to evaluate the association of EA with BMI
through a cross-sectional approach. Information regarding the duration of
medication treatment as well as of psychiatric diseases were unknown and
the UKB sample included presumably a mix of chronic and first-episode
patients. EA was used as a proxy for SES, as it is one of the four criteria in
the SSEP construct. This trait was also tested for association with BMI, body
weight change, and WC change in the Swiss psychiatric cohort to validate
its use in the UKB. First, we examined the interaction between EA and the
use of weight-inducing medications with BMI. Next, we used a two-sample
MR design to estimate the causal effect of EA on BMI in both participants
treated with psychotropic medications with high and low propensity to
induce weight gain (i.e., category 2 and 3 in Supplementary Table 1 vs. the
rest of the defined psychiatric population within the UKB). In other words,
we estimated the causal effect in two distinct groups, to determine
whether there was a difference in the effect of EA on BMI. MR
methodology has been described in detail elsewhere [18]. Briefly, MR is
a statistical method applied to large-scale genetic data, which harnesses
the fact that genetic variants are inherited randomly and independently
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from other risk factors of diseases, to estimate the causal effect of an
exposure on an outcome of interest. The random distribution of genetic
variants at birth minimizes the possibility of confounding or reverse
causation as explanations for the link between the exposure and outcome
in the same way that the allocation of a therapy in a randomized
controlled trial minimizes this possibility (see Supplementary Appendix).
RESULTS
Population characteristics
From the initial cohort of 1807 patients, 966 were included in the
analyses (Supplementary Fig. 1 for patient selection). Clinical and
demographic parameters of the cohort are described in Table 1.
The median SSEP was 61.8 (range= 29.4–86.4) and was used as a
threshold to describe the cohort, stratified as low SSEP (<61.8) and
high SSEP (≥61.8). The median age of the cohort was 40 years
(range= 13–96 years). The proportion of smokers was higher in
the low than in the high SSEP group (52% versus 46%), although
the difference did not reach significance. Men represented 45.8%
of the cohort and were more likely to have a low SSEP than
women (49.8% of men in the low versus 41.7% in the high SSEP
group, p= 0.01). In addition, compared to patients with a high
SSEP, patients with a low SSEP more likely suffered from psychotic
disorders (40.7% versus 31.4%) and were less diagnosed with
depression (15.8% versus 21.3%). The three psychotropic medica-
tion categories were not associated with SSEP groups. Most of the
cohort (60.3%) received medium cardiometabolic risk psychotro-
pic treatment, while a minority received low-risk (19.3%) or high-
risk treatment (20.5%). Based on the first available observation,
patients with a low SSEP had higher BMIs than those with a high
SSEP (median= 23.6 kg/m2 versus 22.7 kg/m2; p= 0.004), with a
trend for a higher prevalence of overweight or obese patients
(overweight proportion: 25.9% in the low and 22.5% in the high
SSEP group and obese proportion: 14.5% versus 10.7%, p= 0.05).
The same trend was observed regarding the proportion of central
obesity (44.5% versus 38.3%, p= 0.08), low HDL-cholesterol (14.9%
versus 9.9%, p= 0.06), and median diastolic blood pressure
(77 mmHg versus 74 mmHg, p= 0.05). Finally, 42% of the total
Table 1. Clinical and demographic parameters of the study sample according to SSEP groups.
N Total sample Low SSEP
(29.4 ≤ SSEP < 61.8)
High SSEP
(61.8 ≤ SSEP ≤ 86.4)
p-valuea
Age, median (range), y 966 40 (13–96) 37 (13–93) 44 (13–96) 0.06
Men, n (%) 966 442 (45.8) 240 (49.8) 202 (41.7) 0.01
Smoking, n (%) 816 397 (48.7) 211 (51.7) 186 (45.6) 0.09
Main diagnosis, n (%) 966 0.02
Psychotic disorders (F20-F24;F28-F29) 348 (36) 196 (40.7) 152 (31.4)
Schizoaffective disorders (F25) 85 (8.8) 47 (9.8) 38 (7.9)
Bipolar disorders (F30-F31) 163 (16.9) 78 (16.2) 85 (17.6)
Depressive disorders (F32-F33) 179 (18.5) 76 (15.8) 103 (21.3)
Organic disorders (F00-F09; F28-F29) 28 (2.9) 12 (2.5) 16 (3.3)
Other 163 (16.9) 73 (15.2) 90 (18.6)
Psychotropic treatment group, n (%)b 966 0.31
Low risk of WG 186 (19.3) 100 (20.8) 86 (17.8)
Medium risk of WG 582 (60.3) 279 (57.9) 303 (62.6)
High risk of WG 198 (20.5) 103 (21.4) 95 (19.6)
Metabolic parameters at first observationc
BMI, median (range), kg/m2 966 23.2 (13.3–54.1) 23.6 (14.5–54.1) 22.7 (13.3– 53.5) 0.004
Overweight (25 ≥ BMI < 30 kg/m2), n (%) 234 (24.2) 125 (25.9) 109 (22.5) 0.05
Obese (BMI ≥ 30 kg/m2), n (%) 122 (12.6) 70 (14.5) 52 (10.7)
WC, median (range), cm 819 87 (28–162) 88 (45–133) 85 (43–162) 0.09
Central obesity (WC ≥ 94 cm in male or ≥88 cm in
female), n (%)
339 (41.4) 182 (44.5) 157 (38.3) 0.08
Hypercholesterolemia (≥5mmol/l), n (%) 678 285 (42) 140 (41.2) 145 (42.9) 0.70
LDL hypercholesterolemia (≥3mmol/l), n (%) 639 236 (36.9) 115 (37) 121 (36.9) 1.00
HDL hypocholesterolemia (≤1mmol/l), n (%) 664 82 (12.4) 49 (14.9) 33 (9.9) 0.06
Fasting hypertriglyceridemia (≥2mmol/l), n (%) 664 99 (14.9) 55 (16.6) 44 (13.2) 0.26
Systolic blood pressure, median (range), mmHg 699 120 (72–206) 120 (80–180) 120 (72–206) 0.60
Diastolic blood pressure, median (range), mmHg 699 75 (40–120) 77 (44–117) 74 (40–120) 0.05
Fasting glucose, median (range), mmol/l 492 5 (3–14.9) 5 (3–14.3) 5 (3–14.9) 0.40
Low and high SSEPs indicate SSEPs lower and higher than the median SSEP, respectively.
BMI body mass index, HDL high-density lipoprotein cholesterol, F00-F33 ICD codes, LDL low-density lipoprotein cholesterol, SSEP Swiss socio-economic
position, WC waist circumference, WG weight gain.
ap-values were calculated using Student t-tests for continuous variables and χ2 test of independence for categorical variables. Significant p-values are indicated
in bold.
bAmisulpride, aripiprazole, haloperidol, lurasidone, and flupentixol were considered as drugs with a low propensity for WG; quetiapine, risperidone,
paliperidone, lithium, mirtazapine, zuclopenthixol, and levomepromazine were classified in the group with medium propensity for WG and valproate,
olanzapine and clozapine were considered as having a high propensity for WG.
cFirst observation includes observations at baseline for 86.6% of the sample, at 1 month for 9.5%, and later for 3.8% of the sample.
C. Dubath et al.
3
Translational Psychiatry          (2021) 11:360 
sample had total hypercholesterolemia, while median systolic
blood pressure and glycaemia were in the range of normal values,
with none of these variables being significantly associated with
SSEP groupings.
Longitudinal association of SSEP and cardiometabolic
parameters
Although we observed significant weight gain over treatment
time, no association between SSEP and cardiometabolic para-
meters during psychotropic treatment was observed in young
patients (<25 years, n= 199) and senior patients (≥65 years, n=
204). However, significant associations were found in the adult
population (n= 526) (Table 2). In this age group, SSEP was an
important risk factor for the incidence of metabolic worsening
during psychotropic treatment: among 366 adult patients without
metabolic syndrome at the beginning of the psychotropic
treatment, 42 new cases occurred over a one-year follow-up;
patients whose SSEP was lower than the median value were three
times more likely to develop metabolic syndrome compared to
patients with higher SSEP (HR= 3.1, 95% CI: 1.5–6.5, Fig. 1). Results
of incidence of individual risk components of metabolic syndrome
are described in Supplementary Appendix and presented in
Supplementary Fig. 2.
Continuous SSEP were significantly negatively associated with
cardiometabolic parameters in adult patients, with an increase of
0.017 kg/m2 in BMI (95% CI: 0.004–0.030), 0.063% in weight
change (95%CI: 0.010–0.116), and 0.141% in WC change (95% CI:
0.044–0.244) per each decrease in SSEP unit (Table 2). Negative
associations were also observed when comparing SSEP groups,
with higher BMI in patients with low versus high SSEP (0.44 kg/m2
(95% CI: 0.06–0.84)), weight change (1.60% (95% CI: 0.09–3.17)),
and WC change (3.17% (95% CI: 0.25–6.10)). In Supplementary
Table 2, adult patients’ characteristics are presented stratified into
the three SSEP groups that were used in those analyses.
Associations between SSEP and lipid parameters, glucose levels,
and blood pressure in the three age groups of the cohort are
described in Supplementary Appendix and shown in Supplemen-
tary Table 3.
Subgroup analyses conducted in adult patients, stratified by
categories of psychotropic treatment showed a stronger associa-
tion between SSEP and BMI in patients receiving high cardiometa-
bolic risk treatments (Table 3). Indeed, a decrease from a high to
low SSEP group was associated with a 0.86 kg/m2 higher BMI (95%
CI: 0.03–1.70) in patients receiving high-risk medications, while no
Table 2. Association between SSEP and BMI, weight change, and waist circumference change in the young, adult, and elderly population.
BMI (kg/m2) Weight change (%) WC change (%)
Young (13 ≤ age<25) N= 199 N= 199 Na= 145
SSEP, E (95% CI) 0 (−0.015; 0.015) 0.009 (−0.057; 0.076) 0.035 (−0.254; 0.326)
Low vs medium SSEP, E (95% CI) −0.39 (−0.84; 0.05) −1.65 (−3.62; 0.30) 3.15 (−5.96; 12.10)
Low vs high SSEP, E (95% CI) −0.18 (−0.68; 0.32) −0.50 (−2.70; 1.66) −0.88 (−10.72; 8.89)
Adult (25 ≤ age<65) N= 526 N= 526 Na= 390
SSEP, E (95% CI) 0.017 (0.004; 0.030)*b 0.063 (0.010; 0.116)* 0.141 (0.044; 0.244)**
Low vs medium SSEP, E (95% CI) 0.12 (−0.20; 0.42) 0.39 (−0.86; 1.61) 4.18 (1.87; 6.50)***
Low vs high SSEP, E (95% CI) 0.44 (0.06; 0.84)* 1.60 (0.09; 3.17)* 3.17 (0.25; 6.10)*
Senior (65 ≤ age < 97) N= 204 N= 204 Na= 117
SSEP, E (95% CI) −0.001 (−0.021; 0.018) 0.011 (−0.075; 0.095) −0.077 (−0.229; 0.083)
Low vs medium SSEP, E (95% CI) 0.31 (−0.21; 0.83) 1.23 (−1.02; 3.51) 1.35 (−2.88; 5.63)
Low vs high SSEP, E (95% CI) −0.12 (−0.68; 0.45) −0.36 (−2.79; 2.11) −2.12 (−6.74; 2.43)
Weight and WC change (in %) were calculated as the difference between the current value and the baseline value divided by the baseline value.
Analyses were performed during a 6-month follow-up period, adjusted by age, sex, first available BMI, diagnosis, risk of psychotropic drug-induced weight
gain and were performed using linear mixed models adjusted in a Bayesian framework and using 1,000,000 Markov chain Monte Carlo iterations. SSEP effect
was estimated (E (95% CI)) on a continuous and categorical scale (three SSEP categories: first quartile defines low SSEP, second and third quartiles medium
SSEP, and fourth quartile high SSEP).
BMI body mass index, SSEP Swiss socio-economic position, WC waist circumference.
Significant p-values are indicated as *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.
aThe number of patients included in this analysis was lower than for BMI and weight because of missing WC data.
bTo understand the magnitude of these results, one can imagine a fictional patient with a baseline BMI of 20, taking a high cardiometabolic risk psychotropic
treatment and with a SSEP of 30 (lowest SSEP value in the adult cohort). His/her BMI would increase by 2.2 kg/m2 (95% CI BMI at 6 months: 21.8–22.6) in
6 months to a value of 22.2 kg/m2, while the same patient with a SSEP of 86 (highest SSEP value of the adult cohort) would increase his/her BMI by 1.2 kg/m2
(95% CI BMI at 6 months: 20.1–22.4) in 6 months to a value of 21.2 kg/m2, translating into a 1 kg/m2 BMI difference after 6 months of treatment attributable to
their SSEP difference.
Fig. 1 Incidence of new onset metabolic syndrome according to
SSEP over one year of psychotropic treatment in the adult
population. Analysis was performed in the adult population (25 ≤
age< 65) and was adjusted by age, sex, first available BMI, diagnosis,
risk of psychotropic drug-induced weight gain, using a Cox
proportional hazards model (n= 366). The number at risk at
baseline: 168 High SSEP vs 198 Low SSEP, at 3 months: 98 High
SSEP vs 109 Low SSEP, at 6 months: 47 High SSEP vs 54 Low SSEP, at
9 months: 29 High SSEP vs 29 Low SSEP, at 12 months: 16 High SSEP
vs 16 Low SSEP. High and Low SSEP groups were defined as SSEP
over (≥61.8) vs under (<61.8) median SSEP, respectively.
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significant association was found in those receiving low-risk
medications. The inverse association between SSEP and WC
change was relatively strong in patients receiving high as well as
low cardiometabolic risk psychotropic medications (0.308% of WC
increase per each SSEP unit decrease in patients receiving high-
risk medications (95% CI: 0.055–0.568) and 0.374% increase in
patients receiving low-risk medications (95% CI: 0.074–0.675)).
Analyses stratified by initial BMI are described in Supplementary
Appendix and in Supplementary Table 4.
The association of EA with BMI, weight change, and WC change
was calculated in a small subset of PsyMetab and PsyClin
participants (n= 199), and the results are presented in Supple-
mentary Table 5.
Epidemiological validation in the UKB
30,334 participants were used for the analysis, including 18,893
controls and 11,441 cases (those taking psychotropic medications
with no or low effect on weight and those taking weight
increasing psychotropic medications according to Supplementary
Table 1: risk 1 and 2 versus 3 and 4). We identified a significant
interaction between high-risk medication use and EA on BMI (p=
0.047). Subgroup analyses revealed that the association between
EA and BMI was stronger in cases (beta: 0.10 SD BMI per 1 SD
decrease in age completed education; 95% CI: 0.08–0.12; p < 5 ×
10−16) than controls (beta: 0.07 SD BMI per 1 SD decrease in age
completed education; 95% CI: 0.05–0.09; p= 2.6 × 10−14). In other
words, every year decrease in age completed education was
associated with an ~0.17 kg/m2 increase in BMI in cases.
Estimating the causal effect of education on BMI using MR
The causal effect was estimated in both psychiatric high-risk and
low-risk medications users within the UKB. Specifically, there were
18,755 controls and 11,314 cases (slightly different than above, as
not all participants passed genetic quality control filters). In both
groups, we found a significant effect of EA on BMI, (Supplemen-
tary Fig. 3) where the causal effect was stronger in cases (beta:
−0.47 SD EA per 1 SD BMI; 95% CI: −0.59 to −0.34; p= 1.3 ×
10−13) than in controls (beta: −0.36 SD EA per 1 SD BMI; 95% CI:
−0.46 to −0.27; p= 8.2 × 10−14), consistent with the epidemiolo-
gical analyses. However, the difference between the two estimates
was not statistically significant (one-tailed, t-test p= 0.101).
DISCUSSION
This study revealed that during the first year of observed
psychotropic treatment with cardiometabolic risk potential, adults
aged 25–65 years with a low SSEP were three times more
susceptible to developing metabolic syndrome compared to
patients with high SSEP. In addition, these same patients with a
low SSEP were particularly susceptible to having a higher BMI,
increased body weight and increased WC when prescribed high-
risk psychotropic medications. We observed consistent results in
the replication analyses in the UKB.
Slightly more women were included in this study, in line with
research conducted in Switzerland showing higher utilization of
mental health services by women [19]. Notably, women were
overrepresented in the high SSEP group. A high SES had
previously been associated with better mental health outcomes
and interestingly, women with schizophrenia were reported to
have a better prognosis than men (with higher remission rates,
fewer relapses) [3, 20, 21]. Whether women are relatively
biologically protected (e.g., via estrogen), or benefit from a more
favorable environment that has a positive impact on mental illness
evolution, or whether having a better recovery enables them to
attain (or maintain) a higher SES remains to be explored.
The median baseline BMI of the entire cohort was significantly
higher in patients with a low SSEP. This result is consistent with
data from the general population [6], and could be in part due to
the influence of SSEP on weight gain induced by previously
prescribed psychotropic medications. Indeed, most patients had
already been hospitalized before study recruitment and were not
medication-naïve.
Table 3. Association between SSEP and BMI, weight change, and waist circumference change stratified by psychotropic medication groups in the
adult population.
BMI (kg/m2) Weight change (%) WC change (%)
High risk drug groupb N= 99 N= 99 Na= 69
SSEP, E (95% CI) 0.026 (−0.002; 0.056) 0.069 (−0.044; 0.178) 0.308 (0.055; 0.568)*
low vs medium SSEP, E (95% CI) 0.09 (−0.60; 0.81) 0.46 (−2.28; 3.21) 5.29 (−0.66; 11.27)
low vs high SSEP, E (95% CI) 0.86 (0.03; 1.70)* 2.40 (0.91; 5.58) 6.27 (−0.99; 13.62)
Medium risk drug groupb N= 307 N= 307 Na= 230
SSEP, E (95% CI) 0.019 (0.001; 0.037)* 0.078 (0.006; 0.151)* 0.059 (−0.042; 0.164)
low vs medium SSEP, E (95% CI) 0.19 (−0.24; 0.61) 0.77 (−1.00; 2.46) 3.24 (0.73; 5.74)*
low vs high SSEP, E (95% CI) 0.46 (−0.07; 0.97) 1.86 (−0.28; 3.98) 2.14 (−0.90; 5.19)
Low-risk drug groupb N= 120 N= 120 Na= 91
SSEP, E (95% CI) 0.003 (−0.028; 0.034) 0.024 (−0.093; 0.139) 0.374 (0.074; 0.675)*
low vs medium SSEP, E (95% CI) 0.03 (−0.63; 0.68) −0.05 (−2.56; 2.36) 6.21 (0.22; 12.34)*
low vs high SSEP, E (95% CI) −0.004 (−0.905; 0.920) 0.34 (−3.09; 3.79) 5.53 (−3.34; 14.46)
Weight and WC change (in %) were calculated as the difference between the current value and the baseline value divided by the baseline value.
Analyses were performed in the adult population (25 ≤ age < 65) during a 6-month follow-up period and adjusted by age, sex, first available BMI, diagnosis and
were performed using linear mixed models adjusted in a Bayesian framework and using 1,000,000 Markov chain Monte Carlo iterations. SSEP effect was
estimated (E (95% CI)) on a continuous and categorical scale (three SSEP categories: first quartile defines low SSEP, second and third quartiles medium SSEP,
and fourth quartile high SSEP).
BMI body mass index, SSEP Swiss socio-economic position, WC waist circumference, WG weight gain.
Significant p-values are indicated as *p ≤ 0.05.
aThe number of patients included in this analysis was lower than for BMI and weight because of missing WC data.
bRisk of drug-induced weight gain differs among psychotropic drugs: High-risk drug group includes patients taking valproate, olanzapine, or clozapine;
medium-risk drug group includes patients taking quetiapine, risperidone, paliperidone, lithium, mirtazapine, zuclopenthixol, or levomepromazine; low-risk
drug group includes patients taking amisulpride, aripiprazole, haloperidol, lurasidone, or flupentixol.
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No significant association between SSEP and any cardiometa-
bolic parameters during treatment with the studied psycho-
tropic medications was found in young and in elderly patients.
However, no information was available on whether young
patients were still living with their parents but, according to the
Swiss Federal Statistical Office, only 20% of young people aged
18–24 years live alone in Switzerland, suggesting that a
significant proportion of young patients likely still lived with
their parents [22]. For such patients, the calculated SSEP actually
reflected the SES of their parents and thus might differ from
their own SES. Similarly, some elderly patients might also live
with their children caring for them, which would also not reflect
their own SES. Moreover, elderly patients living in medico-
welfare establishments were excluded, as the institutional
address would indeed not reflect their personal SES. Therefore,
a selection bias was likely present, excluding the oldest and
more severely ill patients. Taken together, these limitations
might explain the lack of association found in the young and
elderly subpopulations. Besides, since compared to the adult
group aged 25–65 years, the sample size was <50% for the
younger and elderly sample, the impact of socioeconomic
factors in these age groups should be further investigated by
future larger studies.
Except for systolic blood pressure, no statistically significant
association between SSEP and other cardiometabolic parameters
was found (glucose, lipid levels, and diastolic blood pressure) in
any of the age groups. The positive association linking high SSEP
to higher systolic blood pressure is surprising and must be
replicated, as the opposite relationship was reported in the
general population in a recent meta-analysis [23].
Psychiatric illness is associated with a risk of weight gain, and
in this study this risk increases when a psychotropic medication
is introduced. Indeed, the greatest association of SSEP with BMI
was found in patients receiving high-risk medications, while a
weaker association and no association were found in patients
taking medium-risk and low-risk medications, respectively.
Importantly, we also identified a causal effect of EA on BMI in
the UKB psychiatric subpopulation, as shown previously in the
whole UKB [24], and found, independently of the duration of
treatment, a trend for a stronger effect in participants taking
high-risk weight-inducing psychotropic medications compared
to those not taking such medications. Socio-economic inequal-
ities negatively impact patients, especially when they are
exposed to high-risk medications, making the most disadvan-
taged patients more vulnerable to medication-induced cardio-
metabolic adverse effects. The effect of an underlying
environmental factor on BMI (in our study, SSEP or EA) seems
thus to be exacerbated by the presence of an additional risk
factor (in our study, a high-risk medication). This observation also
implies that there is a non-negligible proportion of components
leading to metabolic side effects that are modifiable. Therefore,
targeted interventions could improve outcomes of patients with
low levels of education and/or low SES. Among other explana-
tions, mechanistic insight for medication-induced weight gain
includes changes in appetite regulation [25, 26]. Interestingly,
SES influences diet quality, where people of low SES tend to
follow unhealthier diets than do people of high SES. Indeed, a
recent Swiss study confirmed dietary differences according to
SES indicators, namely education, income, and occupation [27]. It
is therefore possible that increased appetite following psycho-
tropic medication initiation has a greater impact on weight gain
in patients whose diet is less healthy. It is unknown, however,
whether, following prescription of appetite-stimulating medica-
tions, strategies to prevent weight gain (e.g., controlled diet or
more physical exercise) differ between patients with low
compared to higher SES. Educational interventions, which
promote healthy eating, should be encouraged, although the
evidence to date suggests a limited effect if the price is a
deterrent. Strategies involving making healthy food financially
accessible, especially for patients with lower SES, may be a
worthwhile endeavor [28].
The present study has several limitations and strengths. First,
the SSEP score was developed from data recorded in 2000.
Unfortunately, replication of the same SSEP construct with more
recent data is not possible in Switzerland since the census
method has changed. Nonetheless, as socio-economic factors
have a long-term effect, having older data is still relevant.
Assuming that individuals did not move before the study period,
the SSEP reflects the socio-economic environment in which they
grew up or spent their life prior to the intervention. Analyses
with EA were consistent with findings using the SSEP with a
significant association with WC and observed trends for
associations with BMI and weight change. Future studies should
try to determine which of the four criteria used in the SSEP
construct most influences patients’ cardiometabolic outcomes
(i.e., whether income, education, occupation, or housing condi-
tions affect the patient outcome in different ways). Another
limitation of the socio-economic variable used in this study is
that the SSEP index is an ecological measure, with the possibility
of high-SSEP individuals living in low-SSEP neighborhoods and
vice versa. Besides, as the patients’ SES was defined based on
their personal address, homeless patients, those living in
residential facilities, and prisoners, representing a non-
negligible part of the psychiatric population, were not included
in the study (Supplementary Fig. 1). Moreover, both in the Swiss
psychiatric cohort and in the UKB sample, information on illness
duration and severity, prior medication, diet behaviors, alcohol
consumption, and physical activity were not available, prevent-
ing us to adjust the analyses for their potential influence. Despite
these limitations, the inception cohort design and longitudinal
follow-up after treatment initiation enabled the prospective
assessment of SSEP effects on the evolution of cardiometabolic
parameters in response to the initiated psychotropic medication
in a comprehensive Swiss psychiatric sample treated under real-
world conditions. Moreover, the observed inverse association
between SSEP and cardiometabolic worsening being strongest in
the high weight-gain risk medication group strengthens the
validity of our findings. Importantly, the influence of EA on BMI in
subjects taking weight gain-inducing psychotropic medications
was confirmed in a large population-based cohort.
In summary, in addition to other well-described clinical and
environmental risk factors (e.g., young age, first psychotic episode,
and low BMI), low SES was associated with an increased risk of
worsening of cardiometabolic variables following the prescription
of weight gain-inducing psychotropic medications. In all patients,
cardiometabolic risk factors, including SES, should be assessed
and carefully weighed versus the therapeutic benefits of the
prescribed medications.
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